Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations
The tumor suppressor p53 is inactivated by over hundreds of heterogenous mutations in cancer. Here, we purposefully selected phenotypically reversible temperature-sensitive (TS) p53 mutations for pharmacological rescue with thermostability as the compound-screening readout. This rational screening i...
Gespeichert in:
Veröffentlicht in: | Cell reports (Cambridge) 2022-04, Vol.39 (2), p.110622-110622, Article 110622 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 110622 |
---|---|
container_issue | 2 |
container_start_page | 110622 |
container_title | Cell reports (Cambridge) |
container_volume | 39 |
creator | Tang, Yigang Song, Huaxin Wang, Zhengyuan Xiao, Shujun Xiang, Xinrong Zhan, Huien Wu, Lili Wu, Jiale Xing, Yangfei Tan, Yun Liang, Ying Yan, Ni Li, Yuntong Li, Jiabing Wu, Jiaqi Zheng, Derun Jia, Yunchuan Chen, Zhiming Li, Yunqi Zhang, Qianqian Zhang, Jianming Zeng, Hui Tao, Wei Liu, Feng Wu, Yu Lu, Min |
description | The tumor suppressor p53 is inactivated by over hundreds of heterogenous mutations in cancer. Here, we purposefully selected phenotypically reversible temperature-sensitive (TS) p53 mutations for pharmacological rescue with thermostability as the compound-screening readout. This rational screening identified antiparasitic drug potassium antimony tartrate (PAT) as an agent that can thermostabilize the representative TS mutant p53-V272M via noncovalent binding. PAT met the three basic criteria for a targeted drug: availability of a co-crystal structure, compatible structure-activity relationship, and intracellular target specificity, consequently exhibiting antitumor activity in a xenograft mouse model. At the antimony dose in clinical antiparasitic therapy, PAT effectively and specifically rescued p53-V272M in patient-derived primary leukemia cells in single-cell RNA sequencing. Further scanning of 815 frequent p53-missense mutations identified 65 potential PAT-treatable mutations, most of which were temperature sensitive. These results lay the groundwork for repurposing noncovalent antiparasitic antimonials for precisely treating cancers with the 65 p53 mutations.
[Display omitted]
•Rationally identify PAT as a noncovalent mutant p53 rescue compound•PAT meets the three go-to criteria evaluating a first-in-class targeted compound•PAT rescues p53-V272M in patient-derived primary cancer cells at the clinical dose•65 temperature-sensitive p53 mutants can be rescued by PAT
Tang et al. reported that the antiparasitic PAT noncovalently reactivated 65 temperature-sensitive p53 mutants. PAT met the three go-to criteria evaluating a targeted compound and effectively rescued mutant p53 in patient-derived cancer cells at the clinical dose and thus has practical repurposing potential. |
doi_str_mv | 10.1016/j.celrep.2022.110622 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2650252687</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2211124722003709</els_id><sourcerecordid>2650252687</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-8e015a75434bcf14cc92dcf5d47dd784ec9bf27288495fe383c854ceeb0eb1153</originalsourceid><addsrcrecordid>eNp9kE9LxDAQxYMoKuo3EOnRS9dMmjTdiyCL_2BBED2HNJ1KljapSbrgt7drVTw5l5mB9-YxP0LOgS6AQnm1WRjsAg4LRhlbANCSsT1yzBhADozL_T_zETmLcUOnKinAkh-So0JwkBLkMdHPOIxh8NG6t0y7ZAcddLTJmq-t987qLmbJZ84747e6Q5e6jyxgNCNmCfsBg05jwDyi2xm3mA2iyPox6WS9i6fkoJ1O4Nl3PyGvd7cvq4d8_XT_uLpZ54bTKuUVUhBaCl7w2rTAjVmyxrSi4bJpZMXRLOuWSVZVfClaLKrCVIIbxJpiDSCKE3I53x2Cfx8xJtXbOFHqtEM_RsVKQZlgZSUnKZ-lJvgYA7ZqCLbX4UMBVTu-aqNmvmrHV818J9vFd8JY99j8mn5oToLrWYDTn1uLQUVj0RlsbECTVOPt_wmfrZ6P4Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2650252687</pqid></control><display><type>article</type><title>Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Cell Press Free Archives</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Tang, Yigang ; Song, Huaxin ; Wang, Zhengyuan ; Xiao, Shujun ; Xiang, Xinrong ; Zhan, Huien ; Wu, Lili ; Wu, Jiale ; Xing, Yangfei ; Tan, Yun ; Liang, Ying ; Yan, Ni ; Li, Yuntong ; Li, Jiabing ; Wu, Jiaqi ; Zheng, Derun ; Jia, Yunchuan ; Chen, Zhiming ; Li, Yunqi ; Zhang, Qianqian ; Zhang, Jianming ; Zeng, Hui ; Tao, Wei ; Liu, Feng ; Wu, Yu ; Lu, Min</creator><creatorcontrib>Tang, Yigang ; Song, Huaxin ; Wang, Zhengyuan ; Xiao, Shujun ; Xiang, Xinrong ; Zhan, Huien ; Wu, Lili ; Wu, Jiale ; Xing, Yangfei ; Tan, Yun ; Liang, Ying ; Yan, Ni ; Li, Yuntong ; Li, Jiabing ; Wu, Jiaqi ; Zheng, Derun ; Jia, Yunchuan ; Chen, Zhiming ; Li, Yunqi ; Zhang, Qianqian ; Zhang, Jianming ; Zeng, Hui ; Tao, Wei ; Liu, Feng ; Wu, Yu ; Lu, Min</creatorcontrib><description>The tumor suppressor p53 is inactivated by over hundreds of heterogenous mutations in cancer. Here, we purposefully selected phenotypically reversible temperature-sensitive (TS) p53 mutations for pharmacological rescue with thermostability as the compound-screening readout. This rational screening identified antiparasitic drug potassium antimony tartrate (PAT) as an agent that can thermostabilize the representative TS mutant p53-V272M via noncovalent binding. PAT met the three basic criteria for a targeted drug: availability of a co-crystal structure, compatible structure-activity relationship, and intracellular target specificity, consequently exhibiting antitumor activity in a xenograft mouse model. At the antimony dose in clinical antiparasitic therapy, PAT effectively and specifically rescued p53-V272M in patient-derived primary leukemia cells in single-cell RNA sequencing. Further scanning of 815 frequent p53-missense mutations identified 65 potential PAT-treatable mutations, most of which were temperature sensitive. These results lay the groundwork for repurposing noncovalent antiparasitic antimonials for precisely treating cancers with the 65 p53 mutations.
[Display omitted]
•Rationally identify PAT as a noncovalent mutant p53 rescue compound•PAT meets the three go-to criteria evaluating a first-in-class targeted compound•PAT rescues p53-V272M in patient-derived primary cancer cells at the clinical dose•65 temperature-sensitive p53 mutants can be rescued by PAT
Tang et al. reported that the antiparasitic PAT noncovalently reactivated 65 temperature-sensitive p53 mutants. PAT met the three go-to criteria evaluating a targeted compound and effectively rescued mutant p53 in patient-derived cancer cells at the clinical dose and thus has practical repurposing potential.</description><identifier>ISSN: 2211-1247</identifier><identifier>EISSN: 2211-1247</identifier><identifier>DOI: 10.1016/j.celrep.2022.110622</identifier><identifier>PMID: 35417717</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; antimonials ; Antimony - metabolism ; Antimony - pharmacology ; Antimony - therapeutic use ; Antiparasitic Agents ; Drug Repositioning ; drug repurposing ; Humans ; Mice ; Mutation - genetics ; Neoplasms - genetics ; precision medicine ; Temperature ; temperature-sensitive mutations ; tumor suppressor p53 ; Tumor Suppressor Protein p53 - metabolism</subject><ispartof>Cell reports (Cambridge), 2022-04, Vol.39 (2), p.110622-110622, Article 110622</ispartof><rights>2022 The Authors</rights><rights>Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-8e015a75434bcf14cc92dcf5d47dd784ec9bf27288495fe383c854ceeb0eb1153</citedby><cites>FETCH-LOGICAL-c408t-8e015a75434bcf14cc92dcf5d47dd784ec9bf27288495fe383c854ceeb0eb1153</cites><orcidid>0000-0001-6902-3751 ; 0000-0001-8708-9711</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35417717$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tang, Yigang</creatorcontrib><creatorcontrib>Song, Huaxin</creatorcontrib><creatorcontrib>Wang, Zhengyuan</creatorcontrib><creatorcontrib>Xiao, Shujun</creatorcontrib><creatorcontrib>Xiang, Xinrong</creatorcontrib><creatorcontrib>Zhan, Huien</creatorcontrib><creatorcontrib>Wu, Lili</creatorcontrib><creatorcontrib>Wu, Jiale</creatorcontrib><creatorcontrib>Xing, Yangfei</creatorcontrib><creatorcontrib>Tan, Yun</creatorcontrib><creatorcontrib>Liang, Ying</creatorcontrib><creatorcontrib>Yan, Ni</creatorcontrib><creatorcontrib>Li, Yuntong</creatorcontrib><creatorcontrib>Li, Jiabing</creatorcontrib><creatorcontrib>Wu, Jiaqi</creatorcontrib><creatorcontrib>Zheng, Derun</creatorcontrib><creatorcontrib>Jia, Yunchuan</creatorcontrib><creatorcontrib>Chen, Zhiming</creatorcontrib><creatorcontrib>Li, Yunqi</creatorcontrib><creatorcontrib>Zhang, Qianqian</creatorcontrib><creatorcontrib>Zhang, Jianming</creatorcontrib><creatorcontrib>Zeng, Hui</creatorcontrib><creatorcontrib>Tao, Wei</creatorcontrib><creatorcontrib>Liu, Feng</creatorcontrib><creatorcontrib>Wu, Yu</creatorcontrib><creatorcontrib>Lu, Min</creatorcontrib><title>Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations</title><title>Cell reports (Cambridge)</title><addtitle>Cell Rep</addtitle><description>The tumor suppressor p53 is inactivated by over hundreds of heterogenous mutations in cancer. Here, we purposefully selected phenotypically reversible temperature-sensitive (TS) p53 mutations for pharmacological rescue with thermostability as the compound-screening readout. This rational screening identified antiparasitic drug potassium antimony tartrate (PAT) as an agent that can thermostabilize the representative TS mutant p53-V272M via noncovalent binding. PAT met the three basic criteria for a targeted drug: availability of a co-crystal structure, compatible structure-activity relationship, and intracellular target specificity, consequently exhibiting antitumor activity in a xenograft mouse model. At the antimony dose in clinical antiparasitic therapy, PAT effectively and specifically rescued p53-V272M in patient-derived primary leukemia cells in single-cell RNA sequencing. Further scanning of 815 frequent p53-missense mutations identified 65 potential PAT-treatable mutations, most of which were temperature sensitive. These results lay the groundwork for repurposing noncovalent antiparasitic antimonials for precisely treating cancers with the 65 p53 mutations.
[Display omitted]
•Rationally identify PAT as a noncovalent mutant p53 rescue compound•PAT meets the three go-to criteria evaluating a first-in-class targeted compound•PAT rescues p53-V272M in patient-derived primary cancer cells at the clinical dose•65 temperature-sensitive p53 mutants can be rescued by PAT
Tang et al. reported that the antiparasitic PAT noncovalently reactivated 65 temperature-sensitive p53 mutants. PAT met the three go-to criteria evaluating a targeted compound and effectively rescued mutant p53 in patient-derived cancer cells at the clinical dose and thus has practical repurposing potential.</description><subject>Animals</subject><subject>antimonials</subject><subject>Antimony - metabolism</subject><subject>Antimony - pharmacology</subject><subject>Antimony - therapeutic use</subject><subject>Antiparasitic Agents</subject><subject>Drug Repositioning</subject><subject>drug repurposing</subject><subject>Humans</subject><subject>Mice</subject><subject>Mutation - genetics</subject><subject>Neoplasms - genetics</subject><subject>precision medicine</subject><subject>Temperature</subject><subject>temperature-sensitive mutations</subject><subject>tumor suppressor p53</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><issn>2211-1247</issn><issn>2211-1247</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9LxDAQxYMoKuo3EOnRS9dMmjTdiyCL_2BBED2HNJ1KljapSbrgt7drVTw5l5mB9-YxP0LOgS6AQnm1WRjsAg4LRhlbANCSsT1yzBhADozL_T_zETmLcUOnKinAkh-So0JwkBLkMdHPOIxh8NG6t0y7ZAcddLTJmq-t987qLmbJZ84747e6Q5e6jyxgNCNmCfsBg05jwDyi2xm3mA2iyPox6WS9i6fkoJ1O4Nl3PyGvd7cvq4d8_XT_uLpZ54bTKuUVUhBaCl7w2rTAjVmyxrSi4bJpZMXRLOuWSVZVfClaLKrCVIIbxJpiDSCKE3I53x2Cfx8xJtXbOFHqtEM_RsVKQZlgZSUnKZ-lJvgYA7ZqCLbX4UMBVTu-aqNmvmrHV818J9vFd8JY99j8mn5oToLrWYDTn1uLQUVj0RlsbECTVOPt_wmfrZ6P4Q</recordid><startdate>20220412</startdate><enddate>20220412</enddate><creator>Tang, Yigang</creator><creator>Song, Huaxin</creator><creator>Wang, Zhengyuan</creator><creator>Xiao, Shujun</creator><creator>Xiang, Xinrong</creator><creator>Zhan, Huien</creator><creator>Wu, Lili</creator><creator>Wu, Jiale</creator><creator>Xing, Yangfei</creator><creator>Tan, Yun</creator><creator>Liang, Ying</creator><creator>Yan, Ni</creator><creator>Li, Yuntong</creator><creator>Li, Jiabing</creator><creator>Wu, Jiaqi</creator><creator>Zheng, Derun</creator><creator>Jia, Yunchuan</creator><creator>Chen, Zhiming</creator><creator>Li, Yunqi</creator><creator>Zhang, Qianqian</creator><creator>Zhang, Jianming</creator><creator>Zeng, Hui</creator><creator>Tao, Wei</creator><creator>Liu, Feng</creator><creator>Wu, Yu</creator><creator>Lu, Min</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6902-3751</orcidid><orcidid>https://orcid.org/0000-0001-8708-9711</orcidid></search><sort><creationdate>20220412</creationdate><title>Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations</title><author>Tang, Yigang ; Song, Huaxin ; Wang, Zhengyuan ; Xiao, Shujun ; Xiang, Xinrong ; Zhan, Huien ; Wu, Lili ; Wu, Jiale ; Xing, Yangfei ; Tan, Yun ; Liang, Ying ; Yan, Ni ; Li, Yuntong ; Li, Jiabing ; Wu, Jiaqi ; Zheng, Derun ; Jia, Yunchuan ; Chen, Zhiming ; Li, Yunqi ; Zhang, Qianqian ; Zhang, Jianming ; Zeng, Hui ; Tao, Wei ; Liu, Feng ; Wu, Yu ; Lu, Min</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-8e015a75434bcf14cc92dcf5d47dd784ec9bf27288495fe383c854ceeb0eb1153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>antimonials</topic><topic>Antimony - metabolism</topic><topic>Antimony - pharmacology</topic><topic>Antimony - therapeutic use</topic><topic>Antiparasitic Agents</topic><topic>Drug Repositioning</topic><topic>drug repurposing</topic><topic>Humans</topic><topic>Mice</topic><topic>Mutation - genetics</topic><topic>Neoplasms - genetics</topic><topic>precision medicine</topic><topic>Temperature</topic><topic>temperature-sensitive mutations</topic><topic>tumor suppressor p53</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tang, Yigang</creatorcontrib><creatorcontrib>Song, Huaxin</creatorcontrib><creatorcontrib>Wang, Zhengyuan</creatorcontrib><creatorcontrib>Xiao, Shujun</creatorcontrib><creatorcontrib>Xiang, Xinrong</creatorcontrib><creatorcontrib>Zhan, Huien</creatorcontrib><creatorcontrib>Wu, Lili</creatorcontrib><creatorcontrib>Wu, Jiale</creatorcontrib><creatorcontrib>Xing, Yangfei</creatorcontrib><creatorcontrib>Tan, Yun</creatorcontrib><creatorcontrib>Liang, Ying</creatorcontrib><creatorcontrib>Yan, Ni</creatorcontrib><creatorcontrib>Li, Yuntong</creatorcontrib><creatorcontrib>Li, Jiabing</creatorcontrib><creatorcontrib>Wu, Jiaqi</creatorcontrib><creatorcontrib>Zheng, Derun</creatorcontrib><creatorcontrib>Jia, Yunchuan</creatorcontrib><creatorcontrib>Chen, Zhiming</creatorcontrib><creatorcontrib>Li, Yunqi</creatorcontrib><creatorcontrib>Zhang, Qianqian</creatorcontrib><creatorcontrib>Zhang, Jianming</creatorcontrib><creatorcontrib>Zeng, Hui</creatorcontrib><creatorcontrib>Tao, Wei</creatorcontrib><creatorcontrib>Liu, Feng</creatorcontrib><creatorcontrib>Wu, Yu</creatorcontrib><creatorcontrib>Lu, Min</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cell reports (Cambridge)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tang, Yigang</au><au>Song, Huaxin</au><au>Wang, Zhengyuan</au><au>Xiao, Shujun</au><au>Xiang, Xinrong</au><au>Zhan, Huien</au><au>Wu, Lili</au><au>Wu, Jiale</au><au>Xing, Yangfei</au><au>Tan, Yun</au><au>Liang, Ying</au><au>Yan, Ni</au><au>Li, Yuntong</au><au>Li, Jiabing</au><au>Wu, Jiaqi</au><au>Zheng, Derun</au><au>Jia, Yunchuan</au><au>Chen, Zhiming</au><au>Li, Yunqi</au><au>Zhang, Qianqian</au><au>Zhang, Jianming</au><au>Zeng, Hui</au><au>Tao, Wei</au><au>Liu, Feng</au><au>Wu, Yu</au><au>Lu, Min</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations</atitle><jtitle>Cell reports (Cambridge)</jtitle><addtitle>Cell Rep</addtitle><date>2022-04-12</date><risdate>2022</risdate><volume>39</volume><issue>2</issue><spage>110622</spage><epage>110622</epage><pages>110622-110622</pages><artnum>110622</artnum><issn>2211-1247</issn><eissn>2211-1247</eissn><abstract>The tumor suppressor p53 is inactivated by over hundreds of heterogenous mutations in cancer. Here, we purposefully selected phenotypically reversible temperature-sensitive (TS) p53 mutations for pharmacological rescue with thermostability as the compound-screening readout. This rational screening identified antiparasitic drug potassium antimony tartrate (PAT) as an agent that can thermostabilize the representative TS mutant p53-V272M via noncovalent binding. PAT met the three basic criteria for a targeted drug: availability of a co-crystal structure, compatible structure-activity relationship, and intracellular target specificity, consequently exhibiting antitumor activity in a xenograft mouse model. At the antimony dose in clinical antiparasitic therapy, PAT effectively and specifically rescued p53-V272M in patient-derived primary leukemia cells in single-cell RNA sequencing. Further scanning of 815 frequent p53-missense mutations identified 65 potential PAT-treatable mutations, most of which were temperature sensitive. These results lay the groundwork for repurposing noncovalent antiparasitic antimonials for precisely treating cancers with the 65 p53 mutations.
[Display omitted]
•Rationally identify PAT as a noncovalent mutant p53 rescue compound•PAT meets the three go-to criteria evaluating a first-in-class targeted compound•PAT rescues p53-V272M in patient-derived primary cancer cells at the clinical dose•65 temperature-sensitive p53 mutants can be rescued by PAT
Tang et al. reported that the antiparasitic PAT noncovalently reactivated 65 temperature-sensitive p53 mutants. PAT met the three go-to criteria evaluating a targeted compound and effectively rescued mutant p53 in patient-derived cancer cells at the clinical dose and thus has practical repurposing potential.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35417717</pmid><doi>10.1016/j.celrep.2022.110622</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-6902-3751</orcidid><orcidid>https://orcid.org/0000-0001-8708-9711</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2211-1247 |
ispartof | Cell reports (Cambridge), 2022-04, Vol.39 (2), p.110622-110622, Article 110622 |
issn | 2211-1247 2211-1247 |
language | eng |
recordid | cdi_proquest_miscellaneous_2650252687 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Cell Press Free Archives; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Animals antimonials Antimony - metabolism Antimony - pharmacology Antimony - therapeutic use Antiparasitic Agents Drug Repositioning drug repurposing Humans Mice Mutation - genetics Neoplasms - genetics precision medicine Temperature temperature-sensitive mutations tumor suppressor p53 Tumor Suppressor Protein p53 - metabolism |
title | Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A13%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Repurposing%20antiparasitic%20antimonials%20to%20noncovalently%20rescue%20temperature-sensitive%20p53%20mutations&rft.jtitle=Cell%20reports%20(Cambridge)&rft.au=Tang,%20Yigang&rft.date=2022-04-12&rft.volume=39&rft.issue=2&rft.spage=110622&rft.epage=110622&rft.pages=110622-110622&rft.artnum=110622&rft.issn=2211-1247&rft.eissn=2211-1247&rft_id=info:doi/10.1016/j.celrep.2022.110622&rft_dat=%3Cproquest_cross%3E2650252687%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2650252687&rft_id=info:pmid/35417717&rft_els_id=S2211124722003709&rfr_iscdi=true |